529 related articles for article (PubMed ID: 25050456)
41. Dry powder inhalation of colistin in cystic fibrosis patients: a single dose pilot study.
Westerman EM; De Boer AH; Le Brun PP; Touw DJ; Roldaan AC; Frijlink HW; Heijerman HG
J Cyst Fibros; 2007 Jul; 6(4):284-92. PubMed ID: 17185047
[TBL] [Abstract][Full Text] [Related]
42. The effect of early Pseudomonas aeruginosa treatment on lung function in pediatric cystic fibrosis.
Amin R; Lam M; Dupuis A; Ratjen F
Pediatr Pulmonol; 2011 Jun; 46(6):554-8. PubMed ID: 21337727
[TBL] [Abstract][Full Text] [Related]
43. Tobramycin inhalation powder: a review of its use in the treatment of chronic Pseudomonas aeruginosa infection in patients with cystic fibrosis.
McKeage K
Drugs; 2013 Nov; 73(16):1815-27. PubMed ID: 24194436
[TBL] [Abstract][Full Text] [Related]
44. Phase I, Dose-Escalating Study of the Safety and Pharmacokinetics of Inhaled Dry-Powder Vancomycin (AeroVanc) in Volunteers and Patients with Cystic Fibrosis: a New Approach to Therapy for Methicillin-Resistant Staphylococcus aureus.
Waterer G; Lord J; Hofmann T; Jouhikainen T
Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31964790
[TBL] [Abstract][Full Text] [Related]
45. Tobramycin inhalation powder for P. aeruginosa infection in cystic fibrosis: the EVOLVE trial.
Konstan MW; Geller DE; Minić P; Brockhaus F; Zhang J; Angyalosi G
Pediatr Pulmonol; 2011 Mar; 46(3):230-8. PubMed ID: 20963831
[TBL] [Abstract][Full Text] [Related]
46. Model Calculations of Regional Deposition and Disposition for Single Doses of Inhaled Liposomal and Dry Powder Ciprofloxacin.
Martin AR; Finlay WH
J Aerosol Med Pulm Drug Deliv; 2018 Feb; 31(1):49-60. PubMed ID: 28708440
[TBL] [Abstract][Full Text] [Related]
47. Dry powder versus intravenous and nebulized gentamicin in cystic fibrosis and bronchiectasis. A pilot study.
Crowther Labiris NR; Holbrook AM; Chrystyn H; Macleod SM; Newhouse MT
Am J Respir Crit Care Med; 1999 Nov; 160(5 Pt 1):1711-6. PubMed ID: 10556145
[TBL] [Abstract][Full Text] [Related]
48. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group.
Ramsey BW; Pepe MS; Quan JM; Otto KL; Montgomery AB; Williams-Warren J; Vasiljev-K M; Borowitz D; Bowman CM; Marshall BC; Marshall S; Smith AL
N Engl J Med; 1999 Jan; 340(1):23-30. PubMed ID: 9878641
[TBL] [Abstract][Full Text] [Related]
49. Aztreonam inhalation solution for suppressive treatment of chronic Pseudomonas aeruginosa lung infection in cystic fibrosis.
Assael BM
Expert Rev Anti Infect Ther; 2011 Nov; 9(11):967-73. PubMed ID: 22029514
[TBL] [Abstract][Full Text] [Related]
50. Aerosolized antibiotics in cystic fibrosis: an update.
Fiel SB
Expert Rev Respir Med; 2014 Jun; 8(3):305-14. PubMed ID: 24838090
[TBL] [Abstract][Full Text] [Related]
51. Open label study of inhaled aztreonam for Pseudomonas eradication in children with cystic fibrosis: The ALPINE study.
Tiddens HA; De Boeck K; Clancy JP; Fayon M; H G M A; Bresnik M; Derchak A; Lewis SA; Oermann CM;
J Cyst Fibros; 2015 Jan; 14(1):111-9. PubMed ID: 25091537
[TBL] [Abstract][Full Text] [Related]
52. Synergistic activity of phage PEV20-ciprofloxacin combination powder formulation-A proof-of-principle study in a P. aeruginosa lung infection model.
Lin Y; Quan D; Chang RYK; Chow MYT; Wang Y; Li M; Morales S; Britton WJ; Kutter E; Li J; Chan HK
Eur J Pharm Biopharm; 2021 Jan; 158():166-171. PubMed ID: 33253892
[TBL] [Abstract][Full Text] [Related]
53. Colistimethate sodium dry powder for inhalation: a review of its use in the treatment of chronic Pseudomonas aeruginosa infection in patients with cystic fibrosis.
Conole D; Keating GM
Drugs; 2014 Mar; 74(3):377-87. PubMed ID: 24510624
[TBL] [Abstract][Full Text] [Related]
54. The cost effectiveness of dry powder antibiotics for the treatment of Pseudomonas aeruginosa in patients with cystic fibrosis.
Tappenden P; Harnan S; Uttley L; Mildred M; Walshaw M; Taylor C; Brownlee K
Pharmacoeconomics; 2014 Feb; 32(2):159-72. PubMed ID: 24338264
[TBL] [Abstract][Full Text] [Related]
55. Inhaled aztreonam lysine for cystic fibrosis pulmonary disease-related outcomes.
Pesaturo KA; Horton ER; Belliveau P
Ann Pharmacother; 2012; 46(7-8):1076-85. PubMed ID: 22764322
[TBL] [Abstract][Full Text] [Related]
56. Dry powder inhalation containing muco-inert ciprofloxacin and colistin co-loaded liposomes for pulmonary P. Aeruginosa biofilm eradication.
Wang J; Guo Y; Lu W; Liu X; Zhang J; Sun J; Chai G
Int J Pharm; 2024 Jun; 658():124208. PubMed ID: 38723731
[TBL] [Abstract][Full Text] [Related]
57. Suboptimal ciprofloxacin dosing as a potential cause of decreased Pseudomonas aeruginosa susceptibility in children with cystic fibrosis.
Guillot E; Sermet I; Ferroni A; Chhun S; Pons G; Zahar JR; Jullien V
Pharmacotherapy; 2010 Dec; 30(12):1252-8. PubMed ID: 21114393
[TBL] [Abstract][Full Text] [Related]
58. Optimal airway antimicrobial therapy for cystic fibrosis: the role of inhaled aztreonam lysine.
Elborn JS; Henig NR
Expert Opin Pharmacother; 2010 Jun; 11(8):1373-85. PubMed ID: 20426707
[TBL] [Abstract][Full Text] [Related]
59. One-year safety and efficacy of tobramycin powder for inhalation in patients with cystic fibrosis.
Konstan MW; Flume PA; Galeva I; Wan R; Debonnett LM; Maykut RJ; Angyalosi G
Pediatr Pulmonol; 2016 Apr; 51(4):372-8. PubMed ID: 26709158
[TBL] [Abstract][Full Text] [Related]
60. Patient-specific modeling of regional antibiotic concentration levels in airways of patients with cystic fibrosis: are we dosing high enough?
Bos AC; van Holsbeke C; de Backer JW; van Westreenen M; Janssens HM; Vos WG; Tiddens HA
PLoS One; 2015; 10(3):e0118454. PubMed ID: 25734630
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
